80亿美元！Genmab官宣收购Merus

Core Viewpoint - Genmab announced the acquisition of Merus N.V. for $97.00 per share, totaling approximately $8 billion, marking Genmab's largest acquisition to date [1][3] Company Overview - Merus, founded in 2003 and headquartered in the Netherlands, has a key asset, petosemtamab (MCLA-158), which is an EGFR/LGR5 bispecific antibody [3] - The acquisition is expected to significantly accelerate Genmab's transition to a fully integrated model and diversify its revenue sources [4] Clinical Data - Merus presented promising Phase II clinical data for petosemtamab in combination with Keytruda (K drug) for treating locally advanced head and neck squamous cell carcinoma (HNSCC) at ASCO 2025 [3] - The study included 45 patients, showing an overall response rate (ORR) of 63% and a median progression-free survival (mPFS) of 9 months [3] Market Reaction - Following the positive clinical results, Merus's stock price surged over 60%, reaching $68.89 per share, with a total market capitalization of $5.2 billion [3] Strategic Fit - The acquisition aligns with Genmab's long-term strategy and is expected to enhance its oncology portfolio, with plans to launch multiple new drugs by 2027 [4][5] - Genmab aims to leverage its clinical development and commercialization expertise to maximize the potential of petosemtamab [5] Future Projections - Petosemtamab has received two Breakthrough Therapy Designations (BTD) from the FDA and is undergoing two Phase III trials, with top-line results expected in 2026 [5] - Genmab anticipates that petosemtamab could achieve at least $1 billion in annual sales potential by 2029, with prospects for multi-billion dollar revenue thereafter [5]